Ruboxistaurin attenuates diabetic nephropathy via modulation of TGF-β1/Smad and GRAP pathways

Journal of Pharmacy and Pharmacology

Volumn 68, Issue 2, 2016, Pages 219-232

  Al Onazi, Asma S ^a   Al Rasheed, Nouf M ^a   Attia, Hala A ^a,b   Al Rasheed, Nawal M ^a   Ahmed, Raeesa M ^c   Al Amin, Maha A ^a   Poizat, Coralie ^d  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b MANSOURA UNIVERSITY   (Egypt)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

^d KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

diabetic nephropathy; GRAP; ruboxistaurin; smad; TGF 1

Indexed keywords

ALBUMIN; CREATININE; GLUCOSE; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; RUBOXISTAURIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UREA; VALSARTAN; GRB2 PROTEIN, RAT; INDOLE DERIVATIVE; MADH2 PROTEIN, RAT; MADH3 PROTEIN, RAT; MALEIMIDE DERIVATIVE; PROTEIN KINASE C BETA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG EFFICACY; GENE EXPRESSION; GLOMERULOSCLEROSIS; GLUCOSE BLOOD LEVEL; MALE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RAT; RENAL PROTECTION; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETIC NEUROPATHY; UPREGULATION; UREA BLOOD LEVEL; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPLICATION; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; KIDNEY FUNCTION TEST; METABOLISM; PATHOLOGY; WISTAR RAT;

ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; GRB2 ADAPTOR PROTEIN; INDOLES; KIDNEY FUNCTION TESTS; MALE; MALEIMIDES; PROTEIN KINASE C BETA; RATS, WISTAR; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84958787345     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12504     Document Type: Article

References (65)

1. Shumway JT, Gambert SR,. Diabetic nephropathy-pathophysiology and management. Int Urol Nephrol 2002; 34: 257-264.
2. Border WA, Noble NA,. Cytokines in kidney disease: The role of transforming growth factor-beta. Am J Kidney Dis 1993; 22: 105-113.
3. Reeves WB, Andreoli TE,. Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc Natl Acad Sci USA 2000; 97: 7667-7669.
4. Ziyadeh FN,. Evidence for the involvement of transforming growth factor-beta in the pathogenesis of diabetic kidney disease: are Koch's postulates fulfilled? Curr Pract Med 1998; 1: 87-89.
5. Isono M, et al,. Extracellular signal-regulated kinase mediates stimulation of TGF-beta1 and matrix by high glucose in mesangial cells. J Am Soc Nephrol 2000a; 11: 2222-2230.
6. Isono M, et al,. Stimulation of TGF-beta type II receptor by high glucose in mouse mesangial cells and in diabetic kidney. Am J Physiol Renal Physiol 2000b; 278: F830-F838.
7. Sharma K, Ziyadeh FN,. The emerging role of transforming growth factor-beta in kidney diseases. Am J Physiol 1994; 266: F829-F842.
8. Yamamoto T, et al,. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci USA 1993; 90: 1814-1818.
9. Yamamoto T, et al,. Expression of transforming growth factor-beta isoforms in human glomerular diseases. Kidney Int 1996; 49: 461-469.
10. Inoguchi T, et al,. Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 1992; 89: 11059-11063.
11. Ziyadeh FN, et al,. Stimulation of collagen gene expression and protein synthesis in murine mesangial cells by high glucose is mediated by autocrine activation of transforming growth factor-beta. J Clin Invest 1994; 93: 536-542.
12. Koya D, et al,. Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J Clin Invest 1997; 100: 115-126.
13. Kamato D, et al,. Transforming growth factor-β signalling: role and consequences of Smad linker region phosphorylation. Cell Signal 2013; 25: 2017-2024.
14. Schnaper HW, et al,. It's a Smad world: regulation of TGF-beta signaling in the kidney. J Am Soc Nephrol 2002; 13: 1126-1128.
15. Wang W, et al,. Transforming growth factor-beta and Smad signalling in kidney diseases. Nephrology 2005; 10: 48-56.
16. Furuse Y, et al,. Activation of the Smad pathway in glomeruli from a spontaneously diabetic rat model, OLETF rats. Nephron Exp Nephrol 2004; 98: 100-108.
17. Feng GS, et al,. Grap is a novel SH3-SH2-SH3 adaptor protein that couples tyrosine kinases to the ras pathway. J Biol Chem 1996; 271: 12129-12132.
18. Cummins TD, et al,. Quantitative mass spectrometry of diabetic kidney tubules identifies GRAP as a novel regulator of TGF-beta signaling. Biochim Biophys Acta 2010; 1804: 653-661.
19. Nakamura J, et al,. A protein kinase C-beta-selective inhibitor ameliorates neural dysfunction in streptozotocin-induced diabetic rats. Diabetes 1999; 48: 2090-2095.
20. Ishii H, et al,. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996; 272: 728-731.
21. Tuttle KR,. Protein kinase C-beta inhibition for diabetic kidney disease. Diabetes Res Clin Pract 2008; 82: S70-S74.
22. Kelly DJ, et al,. Protein kinase C-beta inhibition attenuates the progression of nephropathy in non-diabetic kidney disease. Nephrol Dial Transplant 2009; 24: 1782-1790.
23. Tuttle KR, et al,. The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 2005; 28: 2686-2690.
24. Motawi TK, et al,. Angiotensin-converting enzyme inhibition and angiotensin AT1 receptor blockade downregulate angiotensin-converting enzyme expression and attenuate renal injury in streptozotocin-induced diabetic rats. Cell Signal 2013; 7: 378-387.
25. Ecder T,. Renal and metabolic effects of valsartan. Anadolu Kardiyol Derg 2014; 14 (Suppl. 2): S14-S19.
26. Zhou G, et al,. Efficacy of aliskiren, compared with angiotensin II blockade, in slowing the progression of diabetic nephropathy in db/db mice: should the combination therapy be a focus? Am J Transl Res 2015; 7: 825-840.
27. Wang W, et al,. Protective effects of aliskiren and valsartan in mice with diabetic nephropathy. J Renin Angiotensin Aldosterone Syst 2014; 15: 384-395.
28. Tominaga N, et al,. Very high doses of valsartan provide renoprotection independently of blood pressure in a type 2 diabetic nephropathy rat model. Nephrology 2009; 14: 581-587.
29. Galle J,. Reduction of proteinuria with angiotensin receptor blockers. Nat Clin Pract Cardiovasc Med 2008; 5 (Suppl. 1): S36-S43.
30. Kalender B, et al,. Renoprotective effects of valsartan and enalapril in STZ-induced diabetes in rats. Acta Histochem 2002; 104: 123-130.
31. Suzuki K, et al,. Renoprotective effects of low-dose valsartan in type 2 diabetic patients with diabetic nephropathy. Diabetes Res Clin Pract 2002; 57: 179-183.
32. Jiao B, et al,. Valsartan attenuated oxidative stress, decreased MCP-1 and TGF-β1 expression in glomerular mesangial and epithelial cells induced by high-glucose levels. Biosci Trends 2011; 5: 173-181.
33. Wang W, et al,. Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ Res 2006; 98: 1032-1039.
34. Wamsley-Davis A, et al,. AT1A-mediated activation of kidney JNK1 and SMAD2 in obstructive uropathy: preservation of kidney tissue mass using candesartan. Am J Physiol Renal Physiol 2004; 287: F474-F480.
35. Wilkinson-Berka JL, et al,. Renoprotective and anti-hypertensive effects of combined valsartan and perindopril in progressive diabetic nephropathy in the transgenic (mRen-2)27 rat. Nephrol Dial Transplant 2001; 16: 1343-1349.
36. Azahar MA, et al,. Hypoglycemic effect of Octomelessumatrana aqueous extract in streptozotocin-induced diabetic rats and its molecular mechanisms. Asian Pac J Trop Med 2012; 5: 875-881.
37. Kelly DJ, et al,. Protein kinase C beta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy. J Am Soc Nephrol 2005; 16: 1654-1660.
38. Tokuyama H, et al,. Protein kinase C β inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Nephrology 2011; 16: 649-655.
39. Davidson EP, et al,. Treatment of streptozotocin-induced diabetic rats with alogliptin: effect on vascular and neural complications. Exp Diabetes Res 2011; 2011: 810469.
40. Hocher B, et al,. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997; 99: 1380-1389.
41. Wilkinson-Berka JL, et al,. ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat. Diabetes 2002; 51: 3283-3289.
42. Fukasawa H, et al,. Treatment with anti-TGF-beta antibody ameliorates chronic progressive nephritis by inhibiting Smad/TGF-beta signaling. Kidney Int 2004; 65: 63-74.
43. Zhang D, et al,. Low-dose paclitaxel ameliorates renal fibrosis in rat UUO model by inhibition of TGF-beta/Smad activity. Lab Invest 2010; 90: 436-447.
44. Isono M, et al,. Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-beta-induced fibronectin in mesangial cells. Biochem Biophys Res Commun 2002; 296: 1356-1365.
45. Keane WF, et al,. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL study. Kidney Int 2003; 63: 1499-1507.
46. Hao HH, et al,. Preventive effects of rutin on the development of experimental diabetic nephropathy in rats. Life Sci 2012; 91: 959-967.
47. Ziyadeh FN, Wolf G,. Pathogenesis of the podocytopathy and proteinuria indiabetic glomerulopathy. Curr Diabetes Rev 2008; 4: 39-45.
48. Kelly DJ, et al,. Effects on protein kinase C-beta inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy. Am J Physiol Renal Physiol 2007; 293: 565-574.
49. Koya D, et al,. Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC beta inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 2000; 14: 439-447.
50. Lewis EJ, et al,. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860.
51. Arai T, Ohashi H,. Angiotensin receptor blockers and microalbuminuria in hypertensive patients with early microalbuminuric stage diabetic nephropathy. Mol Med Rep 2008; 1: 391-393.
52. Sharma K, Ziyadeh FN,. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 1995; 44: 1139-1146.
53. Okazaki Y, et al,. Enhanced TGF-beta/Smad signaling in the early stage of diabetic nephropathy is independent of the AT1a receptor. Clin Exp Nephrol 2007; 11: 77-87.
54. Anderson PW, et al,. Protein kinase C beta inhibition: The promise for treatment of diabetic nephropathy. Curr Opin Nephrol Hypertens 2007; 16: 397-402.
55. Meier M, et al,. Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model. Diabetes Care 2007; 56: 346-354.
56. Ohshiro Y, et al,. Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase C beta-null mice. Diabetes 2006; 55: 3112-3120.
57. Kelly DJ, et al,. Protein kinase C beta inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 2003; 52: 512-518.
58. Wolf G,. Growth factors and the development of diabetic nephropathy. Curr Diab Rep 2003; 3: 485-490.
59. Flanders KC,. Smad3 as a mediator of the fibrotic response. Int J Exp Pathol 2004; 85: 47-64.
60. Flanders KC, et al,. Mice lacking Smad3 are protected against cutaneous injury induced by ionizing radiation. Am J Pathol 2002; 160: 1057-1068.
61. Zhao J, et al,. Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol 2002; 282: L585-L593.
62. Hong SW, et al,. Increased glomerular and tubular expression of transforming growth factor-beta1, its type II receptor, and activation of the Smad signaling pathway in the db/db mouse. Am J Pathol 2001; 158: 1653-1663.
63. Korrapati MC, et al,. Diabetes-induced renal injury in rats is attenuated by suramin. J Pharmacol Exp Ther 2012; 343: 34-43.
64. Gagliardini E, Benigni A,. Role of anti-TGF-beta antibodies in the treatment of renal injury. Cytokine Growth Factor Rev 2006; 17: 89-96.
65. Yu L, et al,. Combining TGF-beta inhibition and angiotensin II blockade results in enhanced antifibrotic effect. Kidney Int 2004; 66: 1774-1784.